Literature DB >> 33999195

Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.

Catarina Geraldes de Frias Gomes1, Alexandra Sofia Ribeiro de Almeida2, Catarina Callé Lucas Mendes3, Pierre Ellul4, Johan Burisch5, Tiffany Buhagiar4, Abigail Attard4, Bobby Lo5, Ryan C Ungaro6, Bárbara Tonilhas da Silva Morão1, Catarina Ferreira Gouveia1, Joana Milheiro Delgado de Carvalho E Branco7, Jaime Manuel Martins Pereira Rodrigues8, Cristina Teixeira9, Maria Francisca Faria Dias de Castro10, Gonçalo Filipe Domingos Nunes11, Mariana Brito11, Marília Cristina de Sousa Antunes2, Paula Maria Ferreira Brinca Borralho Nunes3,12, Joana Maria Tinoco da Silva Torres1.   

Abstract

BACKGROUND: The Montreal classification categorizes patients with ulcerative colitis (UC) based on their macroscopic disease extent. Independent of endoscopic extent, biopsies through all colonic segments should be retrieved during index colonoscopy. However, the prognostic value of histological inflammation at diagnosis in the inflamed and uninflamed regions of the colon has never been assessed.
METHODS: This was a multicenter retrospective cohort study of newly diagnosed patients with treatment-naïve proctitis and left-sided UC. Biopsies from at least 2 colonic segments (endoscopically inflamed and uninflamed mucosa) were retrieved and reviewed by 2 pathologists. Histological features in the endoscopically inflamed and uninflamed mucosa were scored using the Nancy score. The primary outcomes were disease complications (proximal disease extension, need for hospitalization or colectomy) and higher therapeutic requirements (need for steroids or for therapy escalation).
RESULTS: Overall, 93 treatment-naïve patients were included, with a median follow-up of 44 months (range, 2-329). The prevalence of any histological inflammation above the endoscopic margin was 71%. Proximal disease extension was more frequent in patients with histological inflammation in the endoscopically uninflamed mucosa at diagnosis (21.5% vs 3.4%, P = 0.04). Histological involvement above the endoscopic margin was the only predictor associated with an earlier need for therapy escalation (adjusted hazard ratio, 3.69; 95% confidence interval, 1.05-13.0); P = 0.04) and disease complications (adjusted hazard ratio, 4.79; 95% confidence interval, 1.10-20.9; P = 0.04).
CONCLUSIONS: The presence of histological inflammation in the endoscopically uninflamed mucosa at the time of diagnosis was associated with worse outcomes in limited UC.
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Nancy score; diagnosis; histology; limited ulcerative colitis; prognosis

Mesh:

Year:  2022        PMID: 33999195      PMCID: PMC8889288          DOI: 10.1093/ibd/izab069

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   7.290


  21 in total

1.  Development and validation of the Nancy histological index for UC.

Authors:  Aude Marchal-Bressenot; Julia Salleron; Camille Boulagnon-Rombi; Claire Bastien; Virginie Cahn; Guillaume Cadiot; Marie-Danièle Diebold; Silvio Danese; Walter Reinisch; Stefan Schreiber; Simon Travis; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2015-10-13       Impact factor: 23.059

2.  Evaluation of histologic features with potential prognostic value in ulcerative colitis.

Authors:  Cristiana Popp; Florica Stăniceanu; Gianina Micu; Luciana Nichita; Mirela Cioplea; R B Mateescu; Th Voiosu; Liana Sticlaru
Journal:  Rom J Intern Med       Date:  2014 Oct-Dec

3.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.

Authors:  A Bitton; M A Peppercorn; D A Antonioli; J L Niles; S Shah; A Bousvaros; B Ransil; G Wild; A Cohen; M D Edwardes; A C Stevens
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

Review 4.  Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies.

Authors:  Magnus Hofrenning Wanderås; Bjørn A Moum; Marte Lie Høivik; Øistein Hovde
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

5.  Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study.

Authors:  A Lau; N Chande; T Ponich; J C Gregor
Journal:  Aliment Pharmacol Ther       Date:  2008-06-28       Impact factor: 8.171

6.  Microscopic activity in ulcerative colitis: what does it mean?

Authors:  S A Riley; V Mani; M J Goodman; S Dutt; M E Herd
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

7.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Authors:  Robert V Bryant; Daniel C Burger; Joseph Delo; Alissa J Walsh; Sally Thomas; Axel von Herbay; Otto C Buchel; Lydia White; Oliver Brain; Satish Keshav; Bryan F Warren; Simon P L Travis
Journal:  Gut       Date:  2015-05-18       Impact factor: 23.059

Review 8.  Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies.

Authors:  Iril Monstad; Oistein Hovde; Inger Camilla Solberg; Bjørn A Moum
Journal:  Ann Gastroenterol       Date:  2014

Review 9.  Histological evaluation in ulcerative colitis.

Authors:  Tom C DeRoche; Shu-Yuan Xiao; Xiuli Liu
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-06-18

10.  Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.

Authors:  Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2016-06-09       Impact factor: 9.071

View more
  1 in total

Review 1.  When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.

Authors:  Georgios Michalopoulos; Konstantinos Karmiris
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.